Adolor Corp. (MM) (NASDAQ:ADLR)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Adolor Corp. (MM) Charts. Click Here for more Adolor Corp. (MM) Charts.](/p.php?pid=staticchart&s=N%5EADLR&p=8&t=15)
Adolor Corporation (Nasdaq:ADLR) announced that it will participate in
the Lehman Brothers Eleventh Annual Global Healthcare Conference in
Miami, FL. The company’s presentation is
scheduled for 10:15 a.m. (ET) on Wednesday, March 19, 2008.
Michael R. Dougherty, president and chief executive officer, will
present an overview of the company. A live and on-demand webcast of the
presentation will be accessible on the company's website, http://www.adolor.com,
in the "Investor Insights" section during the presentation, and replay
of the presentation, including PowerPoint slides, will be available
within 24 hours of the live presentation.
About Adolor Corporation
Adolor Corporation (Nasdaq:ADLR) is a biopharmaceutical company
specializing in the discovery, development and commercialization of
novel prescription pain management products. Adolor has two lead product
candidates in development: Entereg®
(alvimopan) for the management of the gastrointestinal side effects
associated with opioid use; and, novel Delta opioid receptor agonists
for a variety of pain indications. Adolor and GlaxoSmithKline are
collaborating in the worldwide development and commercialization of Entereg
in multiple indications. Adolor and Pfizer are collaborating in the
worldwide development and commercialization of two Delta agonists for
pain. Adolor also has a number of discovery research programs focused on
the identification of novel compounds for the treatment of pain. By
applying its knowledge and expertise in pain management, along with
ingenuity, Adolor is seeking to make a positive difference for patients,
caregivers and the medical community. For more information, visit www.adolor.com.
This release, and oral statements made with respect to information
contained in this release, may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements include those which express
plan, anticipation, intent, contingency, goals, targets or future
development and/or otherwise are not statements of historical fact. These
statements are based upon management's current expectations and are
subject to risks and uncertainties, known and unknown, which could cause
actual results and developments to differ materially from those
expressed or implied in such statements. Such known risks and
uncertainties relate to, among other factors: the risk that Adolor may
not receive regulatory approval of ENTEREG ®
(alvimopan) for POI, OBD, or any other indication; the risk that the
PDUFA date extended to May 10, 2008 is further extended or not met; the
risk that a risk management plan acceptable to the FDA could materially
adversely affect the commercial prospects for ENTEREG, if regulatory
approval is achieved; the risk that Adolor may not be able to adequately
address the deficiencies in the November 2006 FDA approvable letter; the
risk that Adolor may not obtain FDA approval for ENTEREG in POI, whether
due to Adolor's inability to provide additional data satisfactory to the
FDA to obtain approval for the NDA, the adequacy of the safety and
efficacy data from all of the ENTEREG studies, changing regulatory
requirements, the risk that the FDA may not agree with Adolor's and
GSK's analyses of the ENTEREG studies (including Study 014) and may
evaluate the results of these studies by different methods or conclude
that the results from the studies, whether or not statistically
significant, do not support safety, efficacy, a favorable risk/benefit
profile, or there were human errors in the conduct of the studies, or
otherwise; adverse safety findings in any ENTEREG studies; the risk that
the alvimopan Investigational New Drug Applications (INDs) remain on
clinical hold indefinitely; the risk that filing targets for regulatory
submissions or user fee goal dates are not met; the risk that the
results of other clinical trials of Adolor's drug product candidates,
including our Delta product candidates are not positive; the risk of
product liability claims; reliance on third party manufacturers; the
costs, delays and uncertainties inherent in scientific research, drug
development, clinical trials and the regulatory approval process;
Adolor's history of operating losses since inception and its need for
additional funds to operate its business; Adolor's reliance on its
collaborators, including GSK and Pfizer, respectively in connection with
the development and commercialization of product candidates; market
acceptance of Adolor's products, if regulatory approval is achieved;
competition; and securities litigation.
Further information about these and other relevant risks and
uncertainties may be found in Adolor's Reports on Form 8-K, 10-Q and
10-K filed with the U.S. Securities and Exchange Commission. Adolor
urges you to carefully review and consider the disclosures found in its
filings which are available in the SEC EDGAR database at http://www.sec.gov
and from Adolor at http://www.adolor.com.
Given the uncertainties affecting pharmaceutical companies in the
development stage, you are cautioned not to place undue reliance on any
such forward-looking statements, any of which may turn out to be wrong
due to inaccurate assumptions, unknown risks, uncertainties or other
factors. Adolor undertakes no obligation to (and expressly
disclaims any such obligation to) publicly update or revise the
statements made herein or the risk factors that may relate thereto
whether as a result of new information, future events, or otherwise.
This press release is available on the website http://www.adolor.com.